Bypass surgery may be more expensive than drug-coated stents, but in the long run it's more cost effective for patients with diabetes because of superior long-term clinical outcomes, according to late-breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2012.
An experimental device converted energy from a beating heart to provide enough electricity to power a pacemaker, in a study presented at the American Heart Association's Scientific Sessions 2012. The findings suggest that patients could power their pacemakers -- eliminating the need for replacements when batteries are spent.
Reinforcing its commitment to people with diabetes, Medtronic, Inc. (NYSE: MDT) is promoting its long-standing partnership with the International Diabetes Federation (IDF) through a new initiative surrounding “World Diabetes Day” on Nov. 14 that aims to engage interventional cardiologists worldwide in raising awareness of the connection between diabetes and coronary artery disease.
Medtronic Stent Successfully Treats Long Lesions and Small Vessels, Two Characteristics Typical of Patients with Diabetes, in Multiple StudiesOctober 23, 2012 11:44 am | by Medtronic | News | Comments
For the treatment of long lesions and small vessels –– two challenging characteristics of coronary artery disease commonly found in patients with diabetes –– the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Vascular Solutions, Inc. today announced that it has launched the R-Band radial hemostasis compression device in the United States. Vascular Solutions is the exclusive distributor of the R-Band device in the U.S. under an agreement entered into with Lepu Medical Technology (Beijing) Co., Ltd., the developer and manufacturer of the device.
“Implantable devices can save lives and decrease mortality, they are not a luxury” said Professor Angelo Auricchio, President of the European Heart Rhythm Association (EHRA) of the ESC at the ICD for Life Summit which concluded in Belgrade, Serbia, today. “In the face of the impressive rise in cardiovascular related mortality in Central and Eastern Europe, we need to implement a structured approach...
Catheter balloons are an important device for a variety of cardiovascular treatments. However, their manufacture can be a complicated process that, if completed wrong, can lead to waste and excess costs. This article highlights a number of innovative technologies that are being offered to help balloon manufacturers ensure their products are defect-free the first time.
It’s not the journey, it’s the destination. In the case of interventional cardiovascular devices, both the journey and the destination are vital. These devices need to navigate the tortuous pathways of the vasculature in order to access and treat complex distal lesions. Getting there isn’t always easy.
When a manufacturer picks up a cardiovascular device, they literally hold someone’s life. There is no room for flaws in the quality of this product, or any other in the cardiovascular realm. These devices are shrinking, while becoming increasingly advanced—more intricate parts achieve more complex functions, within a surface area that leaves only enough space for perfection. So the case has never been greater for quality assurance. Conducting risk analysis through variation analysis software can satisfy it.
Medtronic, Inc. (NYSE: MDT), today announced the Japanese regulatory approval and launch of the Advisa DR MRI™ SureScan™ pacing system. The Advisa MRI system is the first and only MR-Conditional pacemaker available to patients in Japan, the world’s second largest market for medical devices.
AngioDynamics, a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it has entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices...
SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University Medical Center (UMC) Ljubljana has transplanted Slovenia's first patient to receive the SynCardia temporary Total Artificial Heart. The patient, 61-year-old Nikola Gašpic, received a matching donor heart on July 1...
Following Health Canada approval, Cook Medical made the Zilver Vena Venous Self-Expanding Stent available to physicians across Canada at the 2012 Annual Meeting of the Canadian Society for Vascular Surgery. Designed to restore blood flow in obstructed iliofemoral veins, Zilver Vena provides physicians with a tool designed specifically for stenting obstructed iliofemoral veins.
Mediware Information Systems, Inc. (Nasdaq:MEDW) announced that the 2012 versions of the company's core blood management software products, including LifeTrak(R) and HCLL(R) Transfusion, have received updated 510(k) clearance by the US FDA. The software systems are used by more than 500 hospital and blood center facilities in the United States, Canada, Ireland, and Singapore...
Analyst Insight: Investors Breathe Sigh of Relief: Boston Scientific Gets First-in-Class FDA Go-AheadOctober 3, 2012 11:17 am | by GlobalData | News | Comments
On September 28, 2012, the US Food and Drug Administration granted the Boston Scientific Corporation (BSX) regulatory approval for its first-in-class subcutaneous implantable defibrillator (S-ICD) system. This S-ICD system establishes the first new category of cardiac rhythm management devices since the introduction of cardiac resynchronization therapy.
Ann Arbor-based Tangent Medical, an innovator in IV therapy products, recently announced it has received FDA 510(k) clearance for the NovaCath™ Secure IV Catheter System, a product designed to set new standards in peripheral IV catheter design, functionality and performance.
The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will revolutionize the stent industry. On September 25th, 2012, Abbott announced the launch of its drug-eluting bioabsorbable stent, Absorb, in Europe, the Middle East and parts of Asia Pacific and Latin America. Absorb, which received CE mark certification in 2011, is used to treat coronary artery disease.
Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has received 510(k) clearance from the Food and Drug Administration to market the Merit Laureate(R) hydrophilic guide wire.
With the goal of improving patient safety and healthcare efficiency, AAMI and UL (Underwriters Laboratories) are joining forces to develop a suite of standards on medical device interoperability-one of the biggest challenges facing the modern healthcare community. The collaboration is a first for AAMI and UL, and comes at a time when many healthcare facilities and manufacturers are grappling...
Primary results from an ongoing trial conducted by Maquet Cardiovascular, a subsidiary of the Swedish Getinge Group, investigating the use of intra-aortic balloon pumps (IABP) as an adjuvant treatment for myocardial infarction (MI) complicated by cardiogenic shock have shown no difference in patient survival compared to standard care alone.
AngioDynamics Earns FDA Clearance for First Vascular Access Product With BioFlo Technology to Reduce Catheter-Related ThrombusAugust 30, 2012 2:24 pm | by GLOBE NEWSWIRE | News | Comments
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration has granted 510(k) clearance for its BioFlo peripherally inserted central catheters (PICCs) with Endexo technology...
Cardiologists are restricting the use of transcatheter aortic valve implantation (TAVI) to very old or very sick patients at high surgical risk, according to research presented at the ESC Congress today. The first results of the Transcatheter Valve Treatment (TCVT) Sentinel Pilot Registry were presented by registry chairman Professor Carlo Di Mario.
Expanding global access to proven cardiovascular treatment options, Medtronic, Inc. (NYSE: MDT) announced today the launch of the Resolute Integrity™ Coronary Stent System in Japan, the world’s second largest market for medical devices. Indicated for the treatment of coronary artery disease, the Resolute Integrity drug-eluting stent offers a combination of superior deliverability...
The Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology (ESC) was created today after a vote at the ESC Congress General Assembly. ACCA was previously the ESC Working Group on Acute Cardiac Care. Today it becomes one of six ESC Associations, whose presidents are invited to ESC Board meetings.
The German Aortic Valve Registry (GARY) was started in July 2010 and is the only registry so far to include both transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacements and repair. The intention is to deliver a complete picture of current and future practice of treating aortic valve disease and to deliver reliable data on the short and long-term outcome of different treatment strategies.